Support Help Line
Dr. Jean-Yves Masson is an oncology researcher at the CHU de Québec-Laval University Research Center, oncology axis, and full professor in the Department of Molecular Biology, Medical Biochemistry and Pathology of the Laval University School of Medicine. He also holds the Canada Research Chair in DNA Repair and Cancer Therapeutics. He is the recipient of numerous awards and has published more than 100 papers in leading scientific journals.
It is well known that genetic mutations can contribute to the development of breast cancer. Dr. Masson’s team is interested in the DNA repair mechanisms that ensure maintenance of genome integrity—in particular homologous recombination (HR)—as well as the therapeutic avenues stemming from them.
Mutations in the BRCA and PALB2 genes affect their DNA surveillance and repair mechanisms. Dr. Masson was the first to discover that mutations in the PALB2 gene represent vulnerabilities that can be targeted using molecules called poly (ADP-ribose) polymerase inhibitors (PARPi). He is developing a synthetic lethality strategy that specifically targets PALB2-mutated cancer cells while sparing healthy cells. Using genomics, Dr. Masson’s team is assessing the impact of the genetic variations catalogued in PALB2 in order to identify those that could be exploited to benefit patients as part of a personalized medicine approach with clinical management based on genetic status.
Dr. Josée Savard is a regular researcher at CHU de Québec-Laval University Research Center, professor of psychology at Laval University, and researcher at the Laval University Cancer Research Center. She is member of the Équipe de recherche Michel-Sarrazin en oncologie psychosociale et soins palliatifs (ERMOS). She is also the co-chair of the Symptom Management and Optimization of Quality of Life axis of the Réseau de recherche en soins palliatifs et de fin de vie funded by the FRQS (2017-2021).. Dr. Savard is an internationally recognized pioneer and leader in the study of insomnia secondary to breast cancer.
Insomnia is a very common condition in people with breast cancer at various points in the care continuum, yet it remains underdiagnosed and undertreated. In 2005, Dr. Savard published the results of her first randomized clinical study demonstrating the efficacy of cognitive behavioural therapy for insomnia (CBT-I) in women undergoing breast cancer treatment. Those results have been validated by many other studies since. Recognizing that CBT-I is efficacious but not widely available to patients, Dr. Savard is pursuing the development of self-administered treatment methods that are less expensive, require fewer professional resources, and are more likely to be implemented as part of routine cancer care without overloading the healthcare system. Insomnet is a fully self-administered CBT-I program available online that was developed specifically to help people with cancer alleviate their insomnia. It comprises a series of modules with interactive features that provide automated but personalized feedback to each participant. A recent study has shown that a stepped-care treatment approach including Insomnet is as efficacious as standard treatment provided face-to-face in a clinic.
Stephanie Wong, MD MPH, is an assistant professor of surgery at McGill Medical School and a breast surgical oncologist at the Jewish General Hospital Segal Cancer Centre in Montreal. Her clinical and research interests focus on surgical outcomes following neoadjuvant treatment and patient populations at high risk for cancer. She is also the director of the High Risk Breast Clinic at the Jewish General Hospital Stroll Cancer Prevention Centre.
While the average Canadian woman has a 12% risk of developing breast cancer in her lifetime, some women are on a high-risk continuum ranging from 20% to 85%. This is true, for example, for women who have previously received chest radiation therapy. For these women, prevention and surveillance strategies are key to managing their breast cancer risk. The choice of prevention strategies is often complex and considers the estimated risk, the risk reduction afforded by these strategies, their potential side effects, and the perceived impact of a breast cancer diagnosis on quality of life. Although endocrine prevention as well as prophylactic bilateral mastectomy considerably reduce risk, they are not associated with a significant improvement in overall survival. Dr. Wong is seeking to better understand the characteristics of the breast cancer subtypes that develop in women who have received chest radiation therapy, their response to treatment, and their prognoses. Such knowledge could influence and assist in decision-making on prevention strategies for these high-risk subgroups.
Alexandra Dubé is a family physician in the Mont-Laurier area. She was 30 years old when she was diagnosed with breast cancer in 2019. As a committed member of the My Active Health support group, she regularly post inspiring slice-of-life testimonials about her “active” everyday routine, which she effectively balance with her family life as well as her return to professional duties. Alexandra Dubé has also taken part in many Foundation’s conferences and was part of the Pink Tour in 2021. This award is presented to her in recognition of her commitment to the cause and her involvement in our community.
Alexandra Dubé’s contagious positive energy and her generosity are huge sources of inspiration to everyone around her.
Carmen G. Loiselle
Taking care of the bone health of women with breast cancer.
Some breast cancer treatments can weaken bones and increase the risk of osteoporosis and fractures. To improve the bone health of women treated for breast cancer, Dr. Carmen Loiselle
and her team set up the Breast and Bone Health program. Women should be made aware of the possible effects of the treatments on their bones and take care of their bone health. The Breast and Bone Health website contains a wealth of information and tips to prevent bone degradation: exercise plans, nutrition facts, lifestyle adaptations and a concrete plan of action for management. Tools have also been developed for health professionals, such as scorecards, information leaflets and training. The Breast and Bone Health team has developed a clinical model that allows a nurse and physiotherapist to adequately intervene in the management of women treated for breast cancer at risk of bone degradation. Breast and Bone Health promotes bone health and improves the quality of life for women.
For more information: https://breastandbonehealth.ca
Dr. Carmen Loiselle is a senior researcher at the Centre for Nursing Research and a Project Director at the Lady Davis Institute for Medical Research at the Jewish General Hospital in Montreal. Dr. Loiselle is Director of the Cancer Nursing Program, and Professor in the Oncology Department and the Ingram School of Nursing at McGill University. Dr. Loiselle was the Program Leader for PORT (Psychosocial Oncology Research Training Program), a 13-year CIHR-funded transdisciplinary research training program. Dr. Loiselle has served as a grant reviewer for CIHR, the National Cancer Institute of Canada (NCIC), the Canadian Breast Cancer Research Initiative (CBCRI), and the FRSQ.
Dr. Loiselle’s research interests include patient information-seeking behaviour and decision making; patient-health care provider communication; psychosocial oncology, and the use of information technology in cancer care.
The Spyder and motorcycle fundraising ride and Ryker draw, in support of the Quebec Breast Cancer Foundation, invites participants to a meeting point from which the ride leaves to follow a secret itinerary in the Quebec City area.
This activity, organized by a great team of volunteers composed of Louise, Pamela, Linda, Christian, Lysane, Claire and Serge, is supported by TY Moteurs and Adrénaline Sport. This team can also count on several people committed to the cause of breast cancer.
Louise Bélanger is a teacher by training. She keeps her heart young through her volunteer work and her many activities on wheels. When Louise was asked to get involved in the organization of the event, she accepted without hesitation and quickly took over. Over the years, Louise has completed 6 editions of the Spyder and Motorcycle Fundraising Rides, which have raised over $170,000 for the Foundation’s financial aid program. Her determination to help is without a doubt her greatest source of motivation to go further each year!
Dr. Peter Siegel
Dr. Siegel is a full professor in the Faculty of Medicine and an associate member of the Departments of Biochemistry, of Anatomy and Cell Biology, and of Oncology at McGill University. He is also a member of the Rosalind and Mooris Goodman Cancer Research Centre at McGill University.
Dr. Siegel’s breast cancer research covers molecular and cell biology, in-vivo modeling and therapeutic development. His work has led to the discovery of unique prognostic markers, drug targets and metabolic vulnerabilities of metastasis, pointing to new therapeutic avenues for treating this major contributor to breast cancer mortality.
Dr. Siegel has authored over 100 scientific articles published in peer-reviewed journals and is the recipient of numerous awards and research grants. His excellence in research, as well as his administrative and mentoring skills, lie at the foundation of the Goodman Research Centre’s success, making it a world leader in the field.
This Scientific Distinction Award therefore highlights the scope and impact of his career.
Prakash Panangaden, Dr. Tarek Hijal, Dr. Pierre Gfeller, Dr. John Kildea, Michel Maksud and Tristan Williams
Along with Dr. Kildea and Laurie Hendren, Dr. Hijal is one of the co-founders of Opal. He is an associate professor in the Gerald Bronfman Department of Oncology at McGill University, a radiation oncologist and the director of the Department of Radiation Oncology at the McGill University Health Centre. His research activities focus on the evaluation of new radiation treatments for breast and rectal cancers, as well as the improvement of radiation therapy care through the use of databases and machine learning.
Opal is a mobile application that places the patient at the centre of their care trajectory. Its co-creation with breast cancer patient Laurie Hendren is indeed a concrete illustration of this focus. Thanks to Opal, patients can overview their appointments, treatment plans, clinical notes and lab results, and also access contextualized and fully explained educational materials and information about the care process. The app also allows patients to fill out online results questionnaires and rate the educational materials to provide feedback to healthcare professionals. Through this innovative two-way exchange, Opal revolutionizes patient-healthcare system interaction, changes that promise the development of many other uses. Today, the application is being implemented in the Medical Oncology Department at the McGill University Health Centre, thanks to the work of Dr. Asselah, and aims to be used throughout the institution in the coming months.
Dr. Marie-Claude Bourgeois-Daignault
Dr. Bourgeois-Daignault is a principal scientist at the Centre hospitalier de l’Université de Montréal (CHUM) research centre.
Dr. Bourgeois-Daignault and her team are working on the development of breast cancer treatments and the characterization of patients who respond, or do not respond, to treatment. To this end, they are studying and optimizing the use of modified, cancer-specific viruses (oncolytics) as immunotherapeutic treatments for cancer. Targeting the cancer-cell destruction without damaging organs, these viruses are considered to be a promising strategy in breast cancer treatment. Since patients do not all respond to treatment in the same way, Dr. Bourgeois-Daignault’s research program aims to predict the response to treatment and to create more effective viruses. In particular, the team is studying the effects of estrogen on the action of these oncolytic viruses.
The quality of the breast cancer research work and the ability to support students are qualities rewarded by the 2020 Emerging Scientist Award.
Chef Olivier Perret
The Renoir en Rose fundraising evening for the benefit of the Quebec Breast Cancer Foundation and the CEDARS Foundation, brings together great Montréal chefs who share the Renoir’s kitchen to concoct a unique and gastronomic feast.
This project was born from the desire of Olivier Perret, the executive chef at the Renoir at Sofitel Montréal Le Carré Doré, to give back to a cause that is dear to him. Since Mr. Perret himself fought cancer a few years ago and his sister has been diagnosed with breast cancer, he decided to put his culinary talents and those of his entourage to use for a fundraising event.
Over the years, Olivier has spearheaded six editions of Renoir en Rose, raising over $300,000 for the cause.
Morag Park, PH.D.
Director of the Goodman Cancer Research Centre at McGill University, Dr. Park is a leader in research on receptor tyrosine kinase (RTK) receptors and oncogenic RTK activation mechanisms in human cancers. She became a leader in the field by studying the breast cancer microenvironment. She established the Breast Cancer Functional Genomics Group and a breast tissue bank at McGill University and is a member of the advisory councils for research of the provincial Cancer Research Network and the for the Canadian Cancer Society. From 2015 to 2017, she chaired the Tumor Microenvironment Network of the American Association for Cancer Research. More than 190 of her articles have been published in leading journals.
She became interested in breast cancer because of its impact on the lives of many women and their families. Compared to other types of cancers, the high prevalence of breast cancer—one in nine women—and the relatively young age of the many women it affects make breast cancer a major research challenge. The development of excellent preclinical models of breast cancer and the ability to study human tumour tissue from a large tumour bank has allowed her team to gain new understanding of the disease, to focus on the reasons why certain tumours do not respond to treatment, and thus to strive to develop new therapeutic strategies.
Dr. Park’s research goals now include understanding the effects of multiple genetic modifications combined with epigenetic events on tumorigenesis and progression in human breast cancer. This research will be combined with a translational breast cancer research initiative, a McGill-MUHC collaboration between core investigative scientists, surgeons, oncologists and pathologists.
Dr. Jean-François Boileau
Dr. Boileau is a surgical oncologist and clinical researcher at the Jewish General Hospital in Montréal. He is assistant professor in the Department of Surgery at McGill University. He has worked as a staff surgeon at the Centre hospitalier universitaire de Montréal (CHUM) and at the Odette Cancer Centre at the Sunnybrooke Health Sciences Centre in Toronto.
His research interests are breast cancer and clinical trials. The main focus of his research aims at using primary systemic therapy, or neoadjuvant therapy, as a more efficient way to study the effects of systemic treatments in people with breast cancer.
Dr. Boileau is the principal investigator of the SN FNAC Trial, a Canadian multicentre study evaluating the accuracy of sentinel node biopsy in node-positive breast cancer patients following neoadjuvant chemotherapy. Other research interests include the identification of better predictors of response to neoadjuvant chemotherapy and early detection of breast cancer.
His work on sentinel node excision has changed practice around the world. His aim is to decrease the occurrence of morbid lymphedema and improve patients’ quality of life.
Dr. Saima Hassan
Dr. Hassan is a surgeon-oncologist at CHUM and an assistant professor in the Department of Surgery at the Université de Montréal. She is a graduate of the Department of General Surgery in McGill University’s Faculty of Medicine. There, she completed a PhD in translational research on diagnostic and prognostic markers in the context of breast cancer metastasis. She completed a fellowship in general surgery oncology, with a focus on breast cancer and melanoma. She completed three years of postdoctoral research studying the pre-clinical role of PARP inhibitors in triple-negative breast cancers at Oregon Health and Science University in Portland, Oregon. Dr. Hassan also performed clinical activities in breast cancer under the supervision of Dr. André Robidoux.
Her main research objective is to better understand the therapeutic approach to triple negative breast cancer. Although three or four types of chemotherapy are the standard of care, it is not known whether all patients need this treatment, with its associated cytotoxic side effects. It is plausible that some patients may benefit from more specific therapy, such as PARP inhibitors. PARP inhibitors target the DNA repair process and are currently being evaluated in clinical trials. Dr. Hassan’s team seeks to better understand the efficacy of PARP inhibitors, both as single agents and in combination using a cell line model, to better select breast cancer patients who could benefit from such treatment.
Dr. Lynn Gauthier
Dr. Gauthier is assistant professor of palliative care in the Department of Family Medicine and Emergency Medicine of the Faculty of Medicine at Laval University. She is also a regular researcher in the oncology axis of the Centre de recherche du CHU de Québec-Université Laval, as well as in the Équipe de Recherche Michel-Sarrazin en oncologie psychosociale et soins palliatifs (ERMOS). She is also co-director of the Axis 1 of the Réseau québécois de recherche en soins palliatifs et de fin de vie (RQSPAL) and a regular member of the Quebec Pain Research Network. She completed her PhD at the School of Kinesiology and Health Sciences at York University in Toronto in 2013 and her post-doctorate at the Princess Margaret Cancer Centre in 2016. Her research examines the intersection of pain and aging. Her main objective is to improve the assessment and management of pain during adulthood, particularly in the geriatric population. Dr. Gauthier aims to deepen our understanding of pain and its management, as well as to identify ways to improve it to reduce patients’ suffering.
The Five Dragon Boat Teams
From left to right:
The dragon-boat movement for breast-cancer survivors is inspired by research by Don McKenzie, a Canadian sports-medicine specialist. It brings breast cancer survivors together to paddle for their physical health and social well-being. Promoting healthy lifestyle habits,
the teams proudly represent the Foundation in activities and competitions throughout the province and sometimes even around the world.
Ms. Robert received the Quebec Breast Cancer Foundation’s Outstanding Engagement Award for her remarkable commitment to Richard and William, whose mother, Yun Min, died of breast cancer in 2017. Young violin prodigies, the two brothers study at the Conservatoire de musique de Montréal. Ms. Robert, who is their violin teacher and a breast cancer survivor herself, took them in while looking for a family to adopt them. Refusing to let these talented children give up their passion, she appealed to the Conservatoire and to the Foundation to create a fund to help them. The Quebec Breast Cancer Foundation is grateful for the generosity of the National Bank for its contribution to this fund.
Jacques Simard and the PERSPECTIVE Project team
The PERSPECTIVE Project (personalized risk stratification for the prevention and early detection of breast cancer) is a major collaboration involving hundreds of researchers from around the world. The Project has identified 72 genetic variations that increase the risk of developing breast cancer. Professor Jacques Simard, researcher in charge of the Centre de recherche du CHU de Québec-Université Laval and the Canada Research Chair in Oncogenetics leads this work. Four years of the PERSPECTIVE Project led this Quebec researcher to obtain data that will provide a better genetic understanding of breast cancer.
The Project aims to develop stratification tools that will make it possible to target breast cancer screening via mammography among the women most likely to develop the disease. This will make it possible to better serve younger women at high risk of developing breast cancer and who are currently outside the standard screening program, due to the age-based eligibility criterion. Given that breast cancer in these young women is often more aggressive, earlier detection and follow-up would make it possible to use less-invasive therapies, reduce treatment side effects, improve survival and increase quality of life.
Susan Mc Peak and Charles Sirois of the McPeak Sirois Group
The McPeak-Sirois Group arose out of the will and hard work of Susan McPeak and Charles Sirois.
Channeling the willpower and expertise of Quebec’s major research centres in the fight against breast cancer, the McPeak-Sirois Group has created a hub that attracts more research protocols to Quebec. More specifically, the Group intends to build a multi-institutional network of clinicians, researchers and members of the medical community involved in clinical breast cancer research. A new approach to the fight against breast cancer.
In 2009, Sylvie Brisebois organized for the first Ride de filles, a motorcycle ride for women. That first year, 50 participants raised $7,000 for the Foundation. Thanks to the commitment of an organizing committee, volunteers and participants, more than 200 people now come together to raise an average of $70,000 every year. In nine years, Sylvie’s initiative has raised close to $400,000. To celebrate its 10th anniversary in 2018, the Ride is aiming to reach $500,000. Singer Lulu Hugues has joined the team as spokesperson.
Ms. Arbour joined the Foundation’s board of directors in 2007, and served as chair from 2014 to 2017. Her commitment as a volunteer was most remarkable and sincere. Her unifying leadership and dedication to the cause paved the way for great achievements. Today, she continues to be generously involved in many organizations.
Drs. Louise Provencher and Sarkis Meterissian
The Quebec Breast Cancer Foundation is proud to count on Drs. Provencher and Meterissian, both surgeon-oncologists involved in clinical research, to head its Breast Health Advisory Committee. Recognized and esteemed by their peers and patients, these two physicians both have an impressive track record. Each works in one of Quebec’s university hospital centres that have obtained the supra-regional designation for breast cancer.
Dr. Provencher is a general surgeon and oncologist at the Centre hospitalier universitaire (CHU) de Québec. Since 2003, she has also served as the medical director for the Centre des maladies du sein Deschênes-Fabia at the Hôpital du Saint-Sacrement, which treats more than 800 new cases of breast cancer annually, making it one of the largest breast cancer centres in Canada. She is also a clinical associate professor in the Department of Surgery in Université Laval’s Faculty of Medicine.
Very involved in clinical research, Dr. Provencher has been the primary investigator or co-investigator for several international multi-centre studies sponsored by prestigious organizations, such as the National Surgical Adjuvant Breast and Bowel Project, the National Cancer Institute of Canada and the Breast Cancer International Research Group, in addition to having worked on studies funded by pharmaceutical companies.
Dr. Provencher has written numerous scientific articles, is a frequent speaker in Quebec and elsewhere in the world, and has organized several conferences on breast cancer. She has received numerous awards and special mentions, including the Award of Excellence from the Collège des médecins du Québec, in recognition of her exceptional work on women with breast cancer over the past 30 years.
Dr. Meterissian is full professor of surgery and oncology, and, since 2006, the director of the Cedars Breast Clinic at the McGill University Health Centre. He is also associate dean of postdoctoral studies at McGill University.
Dr. Meterissian has been a member of the Centre for Medical Education since 2001 and chaired the Canadian Society of Surgical Oncology from 2007 to 2009. He chairs the Committee of Canadian Postgraduate Deans, a committee of the Association of Faculties of Medicine of Canada, and serves as president-elect of the Canadian Association of University and International Breast Surgeons, a division of the International Society of Surgery. He currently sits on the board of directors of the Collège des médecins du Québec.
Appointed professor of general surgery par excellence in 2000 and 2001, as well as professor par excellence by the Department of Surgery in 1996, he was named to the Faculty’s honorary professor list in 2005. In 2007, he won the prestigious Philip J. Wolfson Outstanding Teaching Award, presented by the Association for Surgical Education, which gathers more than 190 medical institutions and schools in North America. Finally, from 2007 to 2009, Dr. Meterissian was a visiting professor in Utrecht and Stockholm.
Dr. Joseph Bou-Mehri, Jacinthe Brodeur, Marie-France Vachon and Louise Handfield, CHUM
We’d like to honour the CHUM team that designed and implemented a significant improvement in practice. Presented in 2014 as part of the Foundation’s One Million to Help competition, the Education and Decision-making Support for Breast Reconstruction Project created and implemented concrete tools to help women before their reconstruction surgery. These included information sheets, videos, preoperative learning sessions and nurses’ systematic patient follow-up, starting at the decision to have surgery and throughout the hospital trajectory, as well as the training of hospital and community workers who interact with these women.
The Project adopted an integrated approach that allows women to be full partners throughout the care trajectory, to be supported and involved from the moment they make a decision to undergo breast reconstruction until they are discharged from hospital following surgery.
For a seventh consecutive year, the Zumbathon at the Centre communautaire Laurent-Venne was a great success! This festive and unifying event would not be what it is without the enthusiastic support of the community centre’s director, Serge Legault, the event’s MCs and the teachers, participants, partners, sponsors, and volunteers who are wholeheartedly involved in this wonderful project.
JoAnne Kelly Rudy Volunteer of the Year Award: Lise Gendron
Lise Gendron has been lending the Quebec Breast Cancer Foundation a hand for 15 years now. She has been a long-time supporter of our weekly activities and, until 2017, spent her summers supporting our teams in getting ready for what was then our biggest annual event: The CIBC Run for the Cure. For 10 years, she managed the food tent, feeding approximately 6,000 people every year. She led a team of volunteers and fully supported event participants.
She continues to lend a hand in preparing our events and on the turf. Her energy and enthusiasm constantly inspire us to go that extra mile.
Dr. André Robidoux
Dr. Robidoux is professor of surgery at the Université de Montréal where he is also the Scotiabank Chair in the Diagnosis and Treatment of Breast Cancer. He directs the Groupe de recherche en cancer du sein du CHUM. Dr. Robidoux was also elected to the board of directors of the National Surgical Adjuvant Breast Project (NSABP) and is a principal investigator of NRG Oncology. He has served on the advisory committee for research of the Canadian Breast Cancer Research Alliance, the Royal College Council and numerous NSABP committees.
In 2010, Dr. Robidoux received the British Journal of Surgery Lecture Award from the Royal College of Surgeons Association of England and the Distinguished Investigator Lifetime Achievement Award from NSABP for his unwavering commitment to NSABP and oncology research. He was also appointed NSABP’s senior liaison officer in Canada. In 2010, Dr. Robidoux was elected to the board of directors of the Canadian Partnership against Cancer and was instrumental in the recent creation of the Quebec-based McPeak-Sirois Research Group, which includes three universities, and chairs its scientific committee.His greatest contribution is the adoption of a scientific approach for the significant contribution of clinical studies in patient management. In 2013, Dr. Robidoux published the book Reasons for Hope: What Research Tells Us about Breast Cancer.
From left to right: Dr. Michel Dorval and Dr. Jocelyne Chiquette (representing the Réseau ROSE), with Angèle Dubeau and Mitsou Gélinas.
Réseau ROSE (Ressources en Oncogénétique pour le Soutien et l’Éducation) network is a group of health professionals, scholars, managers and patients whose mission is to inform and support people at hereditary risk of cancer by making a team of specialized oncogenetic specialists available to them.
Réseau ROSE is the culmination of work begun in 2010 by senior physician Dr. Jocelyne Chiquette and researcher and university professor Dr. Michel Dorval. Inspired by several scientific studies, it stems from the clinical experience of doctors at the Centre des maladies du sein Deschênes-Fabia at the CHU de Québec-Université Laval who have identified the support and information needs of the women at risk of breast cancer and their families. In September 2012, funding from the Quebec Breast Cancer Foundation made it possible to set up the Centre ROSE in Québec City. In 2015, additional funding from the Foundation facilitated the Réseau ROSE, an expansion of the Centre ROSE’s mission to include other partners already working in the field of hereditary cancer.
(left to right) Diane Paquette, Micheline Cloutier-Coffin, Mitsou Gélinas
In 2011, Diane Paquette launched the Rallye pour la Guérison tournament at the Laval sur le Lac golf club. This rally for the cure tournament, open only to the Club’s female members, shows the great solidarity among women in the face of breast cancer. Today, this unifying event raises more than $20,000 a year for the Foundation, for a grand total of $123,500.
Claude Thibault joined the Quebec Breast Cancer Foundation as a volunteer soon after its creation. She has accompanied and supported the Foundation’s teams, both in the offices and in the field, for more than 20 years. Her kindness, generosity and unwavering smile have truly contributed to the Foundation’s development.
Awarded to an individual for the scope and impact of their career. The scientific quality of their research must have resulted in significant advances in the fight against breast cancer.
Awarded to an individual whose work has introduced a remarkable innovation or significantly improved a practice to the benefit of breast cancer patients.
Awarded to young researchers who have stood out by the quality of the projects they presented under the FRQS-FCSQ’s career grant program. Winners receive an additional grant.
This award is not by nomination. Each year, the Fonds de Recherche du Québec – Santé and the Quebec Breast Cancer Foundation present the Scientific Achievement Award to a scholar selected from the FRQS’ career grant program. The program’s aim is to encourage the development of breast cancer research and the education and support of promising young researchers.
Awarded to a volunteer, ambassador, organizer or community initiative organizing committee whose commitment to the Foundation and to the cause has had a major positive impact.
Information and forms regarding the Pam McLernon Volunteer Engagement Award nomination process will be available in October 2022.